Status
Conditions
Treatments
About
The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Provision of written informed consent by the patient OR by the patient's Legal Representative.
Confirmed or suspected SARS-CoV-2 infection;
Pneumonia without criteria of severity.
With some of the following conditions:
Patient who presents negative results by rtPCR for SARS CoV-2, in case of being highly suspicious, the patient may receive it empirically until the results are obtained.
No unstable bronchial asthma
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 1 patient group
Loading...
Central trial contact
Dante M Beltramo, PhD; Nestor H García, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal